Scott WilliamsNuclear MedicineTumor ImagingProstascint (111In-Capromab Pendetide) (CYT-356)Scott WilliamsApr 2, 2002 Prostascint (111In-Capromab Pendetide) (CYT-356) Clinical problem Chemistry and pharmacology Imaging Protocol Interpretation Indications for the exam Dosimetry Complications/Side Effects HAMA Formation (Immunogenicity)Latest in Tumor ImagingTumor > Therapy > Xofigo and other Prostate AgentsAugust 16, 2017SponsoredIMV’s Oncology in Diagnostic Imaging Market Outlook ReportMarch 15, 2024Tumor > OctreotideOctober 31, 2010Tumor > Therapy > MicrospheresJanuary 31, 2008Related StoriesTumor ImagingThallium Tumor Imaging:Tumor ImagingIntroductionTumor ImagingTumor > CEA-scan > Cytogen casesSponsor ContentIMV’s Oncology in Diagnostic Imaging Market Outlook Report